Clinical Trial: Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Open Label Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid, to Determine and Compare in Vivo Brain Uptake and Distribution in Heal

Brief Summary: The study is carried out in order to investigate if [11C]AZD2995, compared to [11C]AZD2184, is a more suitable PET ligand for in vivo imaging of β amyloid depositions in the human brain. In the study the two PET ligands will be examined in both healthy volunteers and patients with Alzheimer's Disease.

Detailed Summary:
Sponsor: AstraZeneca

Current Primary Outcome: Positron emission tomography using the radioligand (11C)AZD2995 or (11C)AZD2184 [ Time Frame: Radioligand (11C)AZD2995.1-2 PET examinations for AD patients and 1 PET examination for healthy volunteers. - Radioligand (11C) AZD2184.One PET for AD patients respective healthy volunteers. ]

Original Primary Outcome: Same as current

Current Secondary Outcome: To assess safety and tolerability of [11C]AZD2995, [11C]AZD2184 and the study procedures, by assessment of adverse events, vital signs and laboratory variables. [ Time Frame: 3-4 visits with tests for the AD patients. 3 visits with tests for the healthy volunteers. All tests are not done at every visit. ]

Original Secondary Outcome: Same as current

Information By: AstraZeneca

Dates:
Date Received: June 5, 2008
Date Started: January 2008
Date Completion:
Last Updated: January 22, 2009
Last Verified: January 2009